Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?
- PMID: 32010633
- PMCID: PMC6979639
- DOI: 10.3389/fonc.2019.01563
Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?
Erratum in
-
Corrigendum: Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?Front Oncol. 2020 Feb 25;10:210. doi: 10.3389/fonc.2020.00210. eCollection 2020. Front Oncol. 2020. PMID: 32161721 Free PMC article.
Abstract
Radiotherapy is a cornerstone of both curative and palliative cancer care. However, radiotherapy is severely limited by radiation-induced toxicities. If these toxicities could be reduced, a greater dose of radiation could be given therefore facilitating a better tumor response. Initial pre-clinical studies have shown that irradiation at dose rates far exceeding those currently used in clinical contexts reduce radiation-induced toxicities whilst maintaining an equivalent tumor response. This is known as the FLASH effect. To date, a single patient has been subjected to FLASH radiotherapy for the treatment of subcutaneous T-cell lymphoma resulting in complete response and minimal toxicities. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy is yet to be elucidated, but the most prominent hypothesis so far proposed is that acute oxygen depletion occurs within the irradiated tissue. This review examines the tissue response to FLASH radiotherapy, critically evaluates the evidence supporting hypotheses surrounding the biological basis of the FLASH effect, and considers the potential for FLASH radiotherapy to be translated into clinical contexts.
Keywords: FLASH; hypoxia; immune; normal tissue; radiotherapy.
Copyright © 2020 Wilson, Hammond, Higgins and Petersson.
Figures
References
-
- NCRAS, CRUK Chemotherapy, Radiotherapy and Tumour Resection By Tumour & Patient Characteristics in England, 2013–2015. National Cancer Registration & Analysis Service and Cancer Research UK (2018).
-
- Jelonek K, Pietrowska M, Widlak P. Systemic effects of ionizing radiation at the proteome and metabolome levels in the blood of cancer patients treated with radiotherapy: the influence of inflammation and radiation toxicity. Int J Radiat Biol. (2017) 93:683–96. 10.1080/09553002.2017.1304590 - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
